Winkelmann N, Hidalgo-Curtis C, Waghorn K, Score J, Dickinson H, Jack A, Ali S, C.P. Cross N: Recurrent CEP85L-PDGFRB fusion in a patient with a t(5;6) and an imatinib-responsive myeloproliferative neoplasm with eosinophilia. Leukemia & Lymphoma (2013). PMID: 23186533
Schnetzke U, Fischer M, Kuhn A-K, Spies-Weisshart B, Zirm E, Hochhaus A, Müller JP, Scholl S: The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells. J Cancer Res Clin Oncol (2013). PMID: 23263202
Ottmann OG, Larson RA, Kantarjian HM, le Coutre PD, Baccarani M, Hochhaus A, Kim DW, Fan X, Novick S, Giles FJ: Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia (2013). PMID: 23138184
Oscier DG, Rose-Zerilli MJJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J, Parker H, Parker A, Gardiner A, Collins A, Else M, Cross NCP, Catovsky D, Strefford JC: The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013. PMID: 23086750
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim D-W, Larson RA, Lipton JH, Mahon F-X, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann J-L, Goldman JM, Hehlmann R: European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013, 122 (6), 827-884. PMID: 23803709
Bähring F, Schlenk F, Wotschadlo J, Buske N, Liebert T, Bergemann C, Heinze T, Hochhaus A, Fischer D, Clement JH: Suitability of Viability Assays for Testing Biological Effects of Coated Superparamagnetic Nanoparticles. IEEE TRANSACTIONS ON MAGNETICS 49 (1), 383-388. DOI: 10.1109/TMAG.2012.2222635
Becker-Putsche M, Bocklitz T, Clement J, Rösch P, Popp J: Towards improving fine needle aspiration cytology by applying Raman microspectroscopy. J Biomed Optics (2013). PMID: 23545854
Boda-Heggemann J, Weiss C, Schneider V, Hofheinz R-D, Haneder S, Michaely H, Wertz H, Ronellenfitsch U, Hochhaus A, Wenz F, Lohr F: Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. Strahlenther Onkol (2013). PMID: 23558673
Cortes J, Digumarti R, Parikh PM, Wetzler M, Lipton JH, Hochhaus A, Craig AR, Benichou A-C, Nicolini FE, Kantarjian HM, Omacetaxine 203 Study Group: Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. American Journal of Hematology (2013). PMID: 23468307
Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H: A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias. N Engl J Med Vol. 369 No. 19. PMID: 24180494
Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A, Nanda N, Benichou A-C, Leonoudakis J, Khoury HJ, Hochhaus A, Baccarani M, Kantarjian HM: Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib. Clinical Lymphoma, Myeloma & Leukemia, Vol. 13, No. 5, 584-91. PMID: 23787123
Dochow S, Beleites C, Henkel T, Mayer G, Albert J, Clement J, Krafft C, Popp J: Quartz microfluidic chip for tumour cell identification by Raman spectroscopy in combination with optical traps. Anal Bioanal Chem (2013). PMID: 23371531
Dochow S, Bergner N, Krafft C, Clement J, Mazilu M, Praveen BB, Ashok PC, Marchington R, Dholakiac K, Popp J: Classification of Raman spectra of single cells with autofluorescence suppression by wavelength modulated excitation. Anal. Methods 2013, 5, 4608. https://doi.org/10.1039/C3AY40193F
Editorial: Die CML-Studiengruppe und die MPN-Intergroup als kooperative Verbünde der akademischen Forschung. Journal Onkologie 2/2013. 69.
Feldmann G, Brossart P, von Lilienfeld-Toal M: Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment. Ann Hematol. (2013). PMID: 23584506
Feldmann G, Brossart P, Zipfel M, von Lilienfeld-Toal M: Mixed response to ipilimumab in a melanoma patient with brain metastases: case report and review of the literature. Case Rep Oncol. 2013, 6 (1), 229-35. PMID: 23687494
Fensterer H, Schade-Brittinger C, Müller H-H, Tebbe S, Fass J, Lindig U, Settmacher U, Schmidt WE, Märten A, Ebert MP, Kornmann M, Hofheinz R, Endlicher E, Brendel C, Barth PJ, Bartsch DK, Michl P, Gress TM: Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Annals of Oncology (2013). PMID: 23897705
Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim D-W, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM: Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013, 27 (1), 107-112. PMID: 22763385
Giles FJ, Mauro MJ, Hong F, Ortmann C-E, McNeill C, Woodman RC, Hochhaus A, le Coutre PD, Saglio G: Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis. Leukemia (2013). PMID: 23459450
Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, LeCoutre PD, Freedman SJ, Cortes JE: MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia 2013, 27 (1), 113-117. PMID: 22772060
Griesshammer M, Ernst T, Schlenk RF, Lengfelder E, Stegelmann F, Reiter A, Döhner K, Koschmieder S: Diagnostik und medikamentöse Therapie der myeloproliferativen Neoplasien (MPN). Journal Onkologie 2/2013, 96-106. PMID: 23404582
Heublein S, Wehner F, Höchsmann B, Hochhaus A, Hartmann M, La Rosée P: Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany. Ann Hematol (2013).
Hochhaus A: Chronische myeloische Leukämie: aktuelle Therapiekonzepte. Pharma Fokus Onkologie 10. Jahrg. 2013, Nr. 1, 4-10.
Hochhaus A: Chronische Myeloische Leukämie (CML). DLH Info 52 III/ 2013.
Hochhaus A: Dosisanpassung nach Verträglichkeit verbessert die Ergebnisse einer intensiven Imatinibtherapie. Kompetenznetz Akute und chronische Leukämien Rundbrief Dezember 2012, 23.
Hochhaus A: Optimierung der Erstlinientherapie der CML mit Nilotinib plus Interferon alpha. Evaluierung der Chance der funktionellen Heilung. TIGER-Studie. Kompetenznetz Akute und chronische Leukämien Rundbrief Dezember 2012, 10-11.
Hochhaus A, Kantarjian H: The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol (2013), 139. 1971-1984. PMID: 23942795
Hochhaus A, La Rosée P: Maßgeschneiderte Therapie der chronischen myeloischen Leukämie. Internist 54, 155–163 (2013). https://doi.org/10.1007/s00108-012-3152-0
Hochhaus A, La Rosée P: Therapie der chronischen myeloischen Leukämie - Offene Fragen und Lösungsansätze. krebsmedizin 22 (2013) Nr. 2, 79-86.
Hochhaus A, La Rosée P, Brümmendorf TH, Burchert A, Saußele S: Chronische myeloische Leukämie - Heilung durch medikamentöse Therapie? Journal Onkologie 2/2013. 77-82.
Hochhaus A, La Rosée P, Mügge L-O, Sayer HG, Scholl S: Zielgerichtete Therapien bei hämatologischen Erkrankungen - Standards und Perspektiven. Der Onkologe (2013).
Hochhaus A, le Coutre PD, Kantarjian HM, Baccarani M, Erben P, Reiter A, McCulloch T, Fan X, Novick S, Giles FJ: Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open‑label, single‑arm A2101 study. J Cancer Res Clin Oncol (2013), 139. 1985-1993. PMID: 24057647
Hochhaus A, Lüftner D, Mackensen A: Gezielte Therapie: alte und neue Hoffnungsträger. Onkologie 2013;36(suppl 5):2–11, https://doi.org/10.1159/000351997
Hochhaus A, Saglio G, Larson RA, Kim D-W, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP: Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013;121(18):3703-3708. doi:10.1182/blood-2012-04-423418. PMID: 23502220
Hochhaus A, Schlag PM, Cordes N, Höffken K: Paul Ehrlichs „magic bullets“. Onkologe 19, 806–808 (2013). https://doi.org/10.1007/s00761-013-2501-5
Hoehler T, von Wichert G, Schimanski C, Kanzler S, Moehler MH, Hinke A, Seufferlein T, Siebler J, Hochhaus A, Arnold D, Hallek M, Hofheinz R, Hacker UT: Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. Br J Cancer. 2013 Sep 17;109(6):1408-13. doi: 10.1038/bjc.2013.409. Epub 2013 Aug 20. PubMed PMID: 23963139; PubMed Central PMCID: PMC3776974. PMID: 23963139
Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, Antonio De Souza C, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A: Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood (2013). PMID: 24335106
Hunstig F, Hammersen J, Kunert C, Petersen I, Merz H, Glaser A, Teichgräber U, Hochhaus A, La Rosée P: Complete Remission After Treatment With Single-Agent Ofatumumab in a Patient With High-Risk Leukemic Mantle-Cell Lymphoma. Journal of Clinical Oncology (2013). PMID: 23690428
Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A: Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia & Lymphoma (2013), Vol 55, No 7. 1451-1462. PMID: 24050507
Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim D-W, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A: Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood (2013).PMID: 24311723
Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller MC, Hanfstein B, Schreiber A, Fabarius A, Pfirrmann M, Schnittger S, Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Krause SW, Heim D, Nerl C, Hossfeld DK, Kolb H-J, Hochhaus A, Hasford J, Hehlmann R, German Chronic Myeloid Leukemia Study Group, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK): Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol (2013). PMID: 24162333
La Rosée P: Die Hämophagozytische Lymphohistiozytose (HLH) und das Makrophagen-Aktivierungs - Syndrom (MAS): Differentialdiagnose bei SIRS, Sepsis und MODS. Intensiv-News (17) 4/ 2013.
La Rosée P, Ernst T, von Bubnoff N, Brümmendorf TH, Hochhaus A: CML: Ursachen und Therapie der Resistenz. Journal Onkologie 2/2013. 89-94.
La Rosée P, Martiat P, Leitner A, Klag T, Müller MC, Erben P, Schenk T, Saussele S, Hochhaus A: Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol (2013) 92. 1345-1350. PMID: 23625298
La Rosée P, Schenk T, Kunert C, Hochhaus A: Die hämophagozytische Lymphohistiozytose (HLH) und das Makrophagenaktivierungssyndrom (MAS): Klinisches Erscheinungsbild und Diagnostik. Laboratoriumsmedizin (2013).
La Rosée P, Stallmach A, Hochhaus A: Jahrestagung der Gesellschaft für Innere Medizin Thüringens e.V. - Pharmakotherapie in der Onkologie: Was der Internist wissen sollte. Ärzteblatt Thüringen 2/ 2013 24. Jahrgang. 98-99.
Lange T, Ernst T, Gruber FX, Maier J, Cross M, Müller MC, Niederwieser D, Hochhaus A, Pfirrmann M: The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica. 2013 May;98(5):714-7. doi: 10.3324/haematol.2012.068890. Epub 2012 Oct 12. PubMed PMID: 23065514; PubMed Central PMCID: PMC3640114.PMID: 23065514
Mahmoudi M, Abdelmonem AM, Behzadi S, Clement JH, Dutz S, Ejtehadi MR, Hartmann R, Kantner K, Linne U, Maffre P, Metzler S, Moghadam M, Pfeiffer C, Rezaie M, Ruiz-Lozano P, Serpooshan V, Shokrgozar M, Nienhaus GU, Parak WJ: Temperature - The “Ignored” Factor at the NanoBio Interface. ACS Nano (2013). PMID: 23808533
Merx K, Fabarius A, Erben P, Griesshammer M, Reiter A, Hofmann W-K, Hehlmann R, Hochhaus A, Lengfelder E: Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study. Ann Hematol (2013). PMID: 23525684
Metzgeroth G, Schwaab J, Gosenca D, Fabarius A, Haferlach C, Hochhaus A, Cross NCP, Hofmann W-K, Reiter A: Long-term follow-up of treatment with imatinib in eosinophiliaassociated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia (2013). PMID: 23615556
Mothes H, Settmacher U, Hochhaus A: 10. Thüringer Krebskongreß im März - Partnerschaftliche Onkologie. Ärzteblatt Thüringen 7-8/ 2013 24. Jahrgang. 404-407.
Müller MC, Dietz C, Fabarius A, Ernst T, Hanfstein B, Lange T, Hochhaus A: CML: Optimierte molekulare und zytogenetische Diagnostik. Journal Onkologie 2/2013. 83-88.
Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M: Infectious Diseases Working Party (AGIHO); German Society of Hematology and Oncology (DGHO). Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2013 92 (4). 433-42.PMID: 23412562
Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Müller MC, Hochhaus A, Dufva IH, Kim D-W, Cortes J, Mauro MJ, Chuah C, Labussière H, Morisset S, Roche-Lestienne C, Lippert E, Hayette S, Peter S, Zhou W, Maguer-Satta V, Michallet M, Goldman J, Apperley JF, Mahon FX, Marin D, Etienne G: The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica (2013). PMID: 23716543
Nieborowska-Skorska M, Hoser G, Hochhaus A, Stoklosa T, Skorski T: Anti-oxidant vitamin E prevents accumulation of imatinibresistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice. Leukemia (2013). PMID: 23604228
Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H: Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial. JAMA 2013 310 (14). 1473-1481. PMID: 24104372
Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Kim D-W, Boultwood J, Rossi F, Gaipa G, De Martini GP, di Celle PF, Jang HG, Fantin V, Bignell GR, Magistroni V, Haferlach T, Pogliani EM, Campbell PJ, Chase AJ, Tapper WJ, Cross NCP, Gambacorti-Passerini C: Recurrent SETBP1 mutations in atypical chronic
myeloid leukemia. Nature Genetics 45 (1). 18-24. PMID: 23222956
Rinke J, Schäfer V, Schmidt M, Ziermann J, Kohlmann A, Hochhaus A, Ernst T: Genotyping of 25 Leukemia-Associated Genes in a Single Work Flow by Next-Generation Sequencing Technology with Low Amounts of Input Template DNA. Clinical Chemistry (2013). PMID: 23592507
Rosendahl J, Brunkhorst FM, Jaenichen D, Strauss B: Physical and mental health in patients and spouses after intensive care of severe sepsis: a dyadic perspective on long-term sequelae testing the Actor-Partner Interdependence Model. Crit Care Med (2013) 41 (1). 69–75.
Schnetzke U, Fischer M, Frietsch JJ, Finkensieper A, Clement JH, Hochhaus A, La Rosée P: Paradoxical MAPK-Activation in Response to Treatment with Tyrosine Kinase Inhibitors in CML: Flow Cytometry Loses Track. Cytometry Part B: Clinical Cytometry (2013). PMID: 23576291
Schnetzke U, Fischer M, Spies-Weisshart B, Zirm E, Hochhaus A, Müller JP, Scholl S: The E3 ubiquitin ligase TRAF2 can contribute to TNF- resistance inFLT3-ITD-positive AML cells. Leukemia Research (2013). PMID: 23998902
Schrenk KG, Krokowski M, Feller AC, Bernhard V, Mügge L-O, Oelzner P, Wolf G, Hochhaus A, Neumann T: Clonal T-LGL population mimicking leukemia in Felty’s syndrome-part of a continuous spectrum of T-LGL proliferations? Ann Hematol (2013). PMID: 23322212
Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny H-P, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann W-K, Cross NCP, Reiter A: Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 22 (14). 2460-2466. PMID: 23958953
Spies-Weisshart B, Schilling K, Böhmer F, Hochhaus A, Sayer HG, Scholl S: Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD). J Cancer Res Clin Oncol 2013, 139. 1397-1404. PMID: 23728535
Stallmach A, Bauer M, Hochhaus A: Klinische Forschung als wichtiger Bestandteil der Weiterbildung in der Inneren Medizin. Ärzteblatt Thüringen 1/ 2012, 23. Jahrgang. 7-8.
Stallmach A, La Rosée P: Entzündung: Mehr als Bakterien oder Viren - Frühjahrstagung der Gesellschaft für Innere Medizin Thüringens e. V. im Rahmen des Internistenkongresses in Wiesbaden. Ärzteblatt Thüringen 6/2013 24. Jahrgang. 343-345.
Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim D-W, Saglio G, Radich JP: Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer (2013).PMID: 23547655
The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM): A Genomics-Based Classification of Human Lung Tumors. Sci Transl Med (2013) 5, 209. PMID: 24174329
Übersicht über die Eckdaten der Studien der MPN- und CML-Studiengruppen mit Kontaktdaten. Journal Onkologie 2/2013. 116.
Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen T-T, Shah NP: Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clinical Pharmacology: Advances and Applications 2013:5. 85-97. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. PMID: 23788844
White HE, Hedges J, Bendit I, Branford S, Colomer D, Hochhaus A, Hughes T, Kamel-Reid S, Kim D-W, Modur V, Müller MC, Pagnano KB, Pane F, Radich J, Cross NCP, Labourier E: Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale. Clinical Chemistry (2013). PMID: 23471097
Yomade O, Spies-Weisshart B, Glaser A, Schnetzke U, Hochhaus A, Scholl S: Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia. Ann Hematol (2013). PMID: 23558906
Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NCP, Reiter A: Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122(14):2460-2466. doi:10.1182/blood-2013-04-496448. PMID: 23958953
Hochhaus A, La Rosée P, Mügge LO, Sayer HG, Scholl S: Zielgerichtete Therapien bei hämatologischen Erkrankungen. Onkologe 19, 835–847 (2013). https://doi.org/10.1007/s00761-013-2497-x
Nieborowska-Skorska M, Hoser G, Hochhaus A, Stoklosa T, Skorski T: Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice. Leukemia. 2013;27(11):2253-2254. doi:10.1038/leu.2013.123. PMID: 23604228
Jabbour E, le Coutre P, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TR, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM:Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia 27, 907–913 (2013). https://doi.org/10.1038/leu.2012.305
Hochhaus A, · Lüftner D, · Mackensen A: Gezielte Therapie: alte und neue Hoffnungsträger, Onkologie 2013;36(suppl 5):2-11, https://doi.org/10.1159/000351997